Literature DB >> 8625318

p27/Kip1 mutation found in breast cancer.

K S Spirin1, J F Simpson, S Takeuchi, N Kawamata, C W Miller, H P Koeffler.   

Abstract

The p27/Kip1 protein belongs to the recently identified family of proteins called cyclin-dependent kinase inhibitors. These proteins play an important role as negative regulators of cell cycle-dependent kinase activity during progression of the cell cycle. Since cyclin-dependent kinase inhibitors can inhibit cell proliferation, they may have a role as tumor suppressor genes. To determine whether p27 alterations may be involved in tumorigenesis, we examined its mutational status in 36 primary breast carcinomas and 9 breast cancer cell lines using PCR-single-strand conformational polymorphism, direct DNA sequencing, and Southern blot analysis. Southern blot analysis showed no homozygous deletions of the p27 gene in either the clinical samples or cell lines. Two point mutations were found in primary tumors. One represents a previously undescribed polymorphism at codon 142; another is a nonsense mutation at codon 104. The latter mutation was absent in the normal matched control sample, and, in addition, it was accompanied with the loss of heterozygosity (LOH) of a microsatellite marker in the vicinity of the p27 gene on chromosome 12p13. These data indicate that p27 mutations are a rare event in breast cancer, but may play an important role in the development of a minority of these cancers. Furthermore, LOH analysis of the 12p13 locus revealed that an additional four of six matched DNA samples had LOH at 12p13 but did not have an alteration of the p27 gene, suggesting that another tumor suppressor gene is located on the short arm of human chromosome 12 which may be frequently involved in the pathogenesis of breast cancers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625318

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  The p27/Kip1 locus shows no loss of heterozygosity in human pituitary adenomas.

Authors:  J C Wilson; J J Zhu; P M Black
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

Review 2.  Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models.

Authors:  Tanya V Kalin; Vladimir Ustiyan; Vladimir V Kalinichenko
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

3.  Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries.

Authors:  L Jin; X Qian; E Kulig; N Sanno; B W Scheithauer; K Kovacs; W F Young; R V Lloyd
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

4.  Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas.

Authors:  Jessica Costa-Guda; Ilaria Marinoni; Sara Molatore; Natalia S Pellegata; Andrew Arnold
Journal:  J Clin Endocrinol Metab       Date:  2011-02-02       Impact factor: 5.958

Review 5.  New insights into the tumor suppression function of P27(kip1)

Authors:  B E Clurman; P Porter
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

6.  Aberrant p27kip1 expression in endocrine and other tumors.

Authors:  R V Lloyd; L Jin; X Qian; E Kulig
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

7.  Screening of cell cycle fusion proteins to identify kinase signaling networks.

Authors:  Michelle Trojanowsky; Dusica Vidovic; Scott Simanski; Clara Penas; Stephan Schurer; Nagi G Ayad
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 8.  Multiple endocrine neoplasia syndromes associated with mutation of p27.

Authors:  M Lee; N S Pellegata
Journal:  J Endocrinol Invest       Date:  2013-06-26       Impact factor: 4.256

9.  The murine gene p27Kip1 is haplo-insufficient for tumour suppression.

Authors:  M L Fero; E Randel; K E Gurley; J M Roberts; C J Kemp
Journal:  Nature       Date:  1998-11-12       Impact factor: 49.962

10.  The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors.

Authors:  Iñigo Landa; Sergio Ruiz-Llorente; Cristina Montero-Conde; Lucía Inglada-Pérez; Francesca Schiavi; Susanna Leskelä; Guillermo Pita; Roger Milne; Javier Maravall; Ignacio Ramos; Víctor Andía; Paloma Rodríguez-Poyo; Antonino Jara-Albarrán; Amparo Meoro; Cristina del Peso; Luis Arribas; Pedro Iglesias; Javier Caballero; Joaquín Serrano; Antonio Picó; Francisco Pomares; Gabriel Giménez; Pedro López-Mondéjar; Roberto Castello; Isabella Merante-Boschin; Maria-Rosa Pelizzo; Didac Mauricio; Giuseppe Opocher; Cristina Rodríguez-Antona; Anna González-Neira; Xavier Matías-Guiu; Pilar Santisteban; Mercedes Robledo
Journal:  PLoS Genet       Date:  2009-09-04       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.